Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
On August 31, 2022, Nanobiotix reported a total of 34,875,872 shares outstanding, with voting rights totaling 36,274,272 theoretical rights and 36,250,130 exercisable rights. This announcement aligns with regulations from the French Financial Markets Authority, ensuring transparency in shareholder voting. Nanobiotix focuses on innovative therapeutic approaches for cancer treatment, utilizing its nanoparticle technology, specifically targeting head and neck cancers. Investors can find further details on their official website.
Nanobiotix and LianBio have announced the enrollment of the first patient in the pivotal Phase 3 NANORAY-312 trial for NBTXR3, targeting elderly patients with locally advanced head and neck cancer ineligible for platinum-based chemotherapy. This trial will assess the effectiveness of NBTXR3 combined with radiotherapy and cetuximab. With a global enrollment goal of 500 patients, LianBio aims to enroll approximately 100 in Asia. Previous trials show promising survival rates, positioning NBTXR3 as a potential key treatment in a rapidly growing radiotherapy market in Asia.
Nanobiotix (NASDAQ: NBTX), a late-stage biotechnology company, announced the participation of co-founder Laurent Levy and CFO Bart Van Rhijn at the H.C. Wainwright 24th Annual Global Investment Conference in New York and virtually from September 12-14, 2022.
Their presentation is scheduled for September 12, 2022, at 2:00 PM ET. A live webcast will be available on the company's website, with a replay accessible within 48 hours.
Nanobiotix has announced the total outstanding shares as of July 31, 2022, amounting to 34,875,872. The total number of voting rights is reported as 36,274,272 (theoretical) and 36,299,593 (exercisable). This financial disclosure aligns with the regulatory requirements under French commercial law. The company focuses on innovative treatments through its nanoparticle platform, particularly for solid tumors and head and neck cancers.
NANOBIOTIX (NASDAQ: NBTX) released its Half-Year report on its liquidity contract with Gilbert Dupont. As of June 30, 2022, the liquidity account held 25,706 shares and a cash balance of €60,051.07. In the first half of 2022, the total buy side traded volume reached 306,341 shares, amounting to €1,883,900.28, while the sell side traded volume was 296,091 shares, totaling €1,846,535.38. Comparatively, as of December 31, 2021, the account held 15,456 shares and €97,415.97 in cash. The report complies with AMF Decision N°2021-01 on liquidity contracts.
Nanobiotix, traded on NASDAQ as NBTX, reported its share structure as of June 30, 2022. The total number of outstanding shares is 34,875,872, with 36,329,077 theoretical voting rights and 36,303,371 exercisable voting rights. This data is critical for investors tracking corporate governance and voting processes. Nanobiotix is dedicated to innovative cancer therapies, particularly focusing on head and neck cancers using its proprietary nanoparticle platform.
Nanobiotix (Euronext: NANO, Nasdaq: NBTX) reported its outstanding shares on May 31, 2022, totaling 34,875,872. The total number of gross voting rights reached 36,393,442, while the net voting rights stood at 36,373,830. This update aligns with regulatory requirements set by the French Financial Markets Authority. As a late-stage clinical biotechnology firm, Nanobiotix focuses on developing innovative therapies for solid tumors, particularly in head and neck cancers, utilizing its proprietary nanoparticle platform.
NANOBIOTIX (Nasdaq: NBTX) reported promising results for its radioenhancer NBTXR3 at the 2022 ASCO Annual Meeting. In a phase 1b/2 study involving 12 patients with stage 4 head and neck cancer, NBTXR3 combined with chemoradiation demonstrated a 100% disease control rate and a 58.3% overall response rate. Similarly, in a rectal cancer study of 31 patients, there was a 100% disease control rate, with 96% of patients eligible for R0 surgery. The data supports NBTXR3's potential for improving treatment outcomes across solid tumors.
NANOBIOTIX, a late-stage clinical biotechnology firm, has announced its Annual Combined Shareholders General Meeting set for June 23, 2022, at 9:30 AM CET in Paris. Shareholders can find the meeting's agenda and details published on May 18, 2022, in the Bulletin des Annonces Légales Obligatoires. Additionally, they can access relevant documents on the company's website. The firm is focused on its innovative oncology product, NBTXR3, which shows promise in treating solid tumors using radiotherapy. A financial agenda for updates in September and November has also been outlined.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
